Nitric oxide synthase inhibitors in experimental stroke and their effects on infarct size and cerebral blood flow; a systematic review

Mark Willmot [1], Claire Gibson [1,2], Laura Gray [1], Sean Murphy [1,2], Philip M W Bath [1]

Institutes of Neuroscience [1] and Cell Signalling [2], University of Nottingham, Nottingham UK

Correspondence:
Professor P Bath
Division of Stroke Medicine
University of Nottingham
Queen's Medical Centre
Nottingham NG7 2UK

Tel: 0115 840 4791
Fax: 0115 840 4790

Email: philip.bath@nottingham.ac.uk

ABSTRACT

Gene knock-out studies in acute experimental stroke suggest that nitric oxide (NO) produced by the neuronal or inducible isoforms of nitric oxide synthase (nNOS, iNOS) is detrimental, whilst that derived from the endothelial isoform (eNOS) is beneficial. However, experimental studies with nitric oxide synthase inhibitors (NOS inhibitors) have given conflicting results.

Published controlled studies of NOS inhibitors in experimental stroke were identified from EMBASE, PubMed and reference lists. Data on the effect of NOS inhibition on lesion volume (mm^3, %) and cerebral blood flow (CBF, %, $ml.min^{-1}.g^{-1}$) were extracted and analysed using the Cochrane Review Manager software.

72 studies were identified. NOS inhibitors reduced total infarct volume in permanent (standardised mean difference, SMD -0.51, 95% confidence intervals, 95% CI -0.82, -0.20) and transient (SMD -1.01, 95% CI −1.29, -0.73) experimental stroke. Similar reductions in lesion volume were present in cortical and sub-cortical areas in both models. Cortical CBF was reduced in permanent (SMD -0.80, 95% CI −1.34, -0.27) but not transient stroke. When assessed by type of inhibitor, total lesion volume was reduced in permanent models by nNOS (SMD -1.36, 95% CI -0.67, -2.05) and iNOS (SMD -0.92, 95% CI −1.16, -0.69) inhibitors, but not by non-selective inhibitors. All types of NOS inhibitors reduced infarct volume in transient models.

Selective inhibitors of nNOS and iNOS appear to reduce lesion volume in both permanent and transient models of cerebral ischaemia. The lack of effect on lesion size by non-selective inhibitors could reflect co-inhibition of eNOS. NOS inhibition may have negative effects on CBF but further studies are required. Selective nNOS and iNOS inhibitors are candidate treatments for acute ischaemic stroke.

Key Words: Nitric oxide, nitric oxide synthase inhibitor, nitric oxide synthase, stroke, animal

Running title: Nitric oxide synthase inhibitors in stroke models

INTRODUCTION

Nitric oxide (NO) is synthesised from its precursor L-arginine by the action of nitric oxide synthase (NOS). NO is produced in the brain following the onset of cerebral ischaemia (Malinski et al 1993), although its precise role in the pathophysiology of stroke is unclear. Gene knockout studies have determined that NO derived from the endothelial isoform of NOS (eNOS) is beneficial in acute stroke (Huang et al. 1996). This may be due, in part, to antiplatelet effects (Welch and Loscalzo 1994) and preservation of cerebral blood flow (Iadecola et al. 1994). In contrast, NO produced by the neuronal and inducible isoforms of NOS (nNOS, iNOS) can be neurotoxic (Huang et al. 1994; Zhao et al. 2000). This probably occurs through NO induced formation of peroxynitrite (Beckman et al. 1990) and toxic free radicals leading to damage by lipid peroxidation (Radi et al. 1991). NO further potentiates damage by inhibiting enzymes needed for mitochondrial respiration (respiratory chain complex 1 and 2), glycolysis (GAPDH) and DNA replication (ribonucleotide reductase) (Dawson et al. 1992b; Dimmeler and Brune 1993; Garthwaite 1991; Nathan 1992). Moreover, NO has been reported to stimulate the release of the neurotransmitter glutamate and could contribute to excitotoxicity (Montague et al. 1994; Sorkin 1993). Consequently, inhibition of NO production has been considered to be a candidate treatment for acute stroke.

The first NOS inhibitors were the guanidino aminoacids, many of which act competitively at the NOS active site. Examples include, N^G-nitro-L-arginine (L-NNA), N^G-nitro-L-arginine methyl ester (L-NAME, a methyl ester pro-drug that is activated to become L-NNA) and N^G-monomethyl-L-arginine (L-NMMA). Both L-NAME and L-NNA exhibit greater *in-vitro* potency than L-NMMA in inhibiting nNOS and eNOS versus iNOS. However, none of the guanidino aminoacids discriminate sufficiently to enable them to be used to target a single NOS isoform. By contrast, some inhibitors possess higher affinity against one isoform and are commonly referred to as 'selective', although this term is used rather indiscriminately (Alderton et al. 2001). Agents that are used to target iNOS include: aminoguanidine, N^G-iminoethyl-L-lysine (L-NIL), N^G-iminoethyl-L-ornithine (L-NIO), the bis-isothioureas (PBITU) (Garvey et al. 1994), 1400W (N-[3-(aminomethyl)benzyl]acetamidine), GW273629 and GW274150 (Young et al. 2000). Other agents are used to target nNOS and include: 7-nitroindinazole (7-NI), tri(fluoromethylphenyl)imidazole (TRIM) (Handy et al. 1995), ARL 17477, AR-R18512 (Reif et al. 2000), BN 80933 (Chabrier et al. 1999), S-ethyl and S-methyl thiocitrulline and vinyl L-NIO. Recent *in-vitro* studies have suggested that in some cases the distinction between selective iNOS and selective nNOS inhibitor may not be straightforward. For example, aminoguanidine is only mildly selective against nNOS *in-vitro* (~5 fold) and probably affects other molecular targets (Alderton et al. 2001). Similarly, 7-NI has been found to be an equipotent inhibitor of all three isoforms of NOS at the isolated enzyme level (Alderton et al. 2001; Escott et al. 1998) although it has more selectivity for nNOS *in vivo*, possibly a consequence of cell specific effects (neuronal verses endothelial) (Alderton et al. 2001).

Pre-clinical studies of all of these agents have given variable results for effects on lesion size and cerebral blood flow (CBF) in animal models of cerebral ischaemia (Willmot and Bath 2003). Hence, the aim of the present investigation was to determine systematically what effect NOS inhibitors have on these parameters.

METHODS

Study identification

Experimental studies assessing the effects of NOS inhibitors on stroke lesion volume and cerebral blood flow (CBF) in ischaemic stroke models (transient or permanent, global or focal, any species) were identified. Searches were made of 'EMBASE' and 'Pubmed' by MW for articles published from 1980 - 2002. For the EMBASE search four primary keywords (nitric oxide, brain, ischaemia, non-human) were chosen combined with a fifth chosen from a list of NOS inhibitors. Different primary keywords were used in the Pubmed search (nitric oxide, cerebro*, ischaemia) which was then limited to animal studies. Other publications were found from reference lists and review articles by CG, SM and PB. Abstracts were then used to select relevant articles for an examination of the full publication by MW. Final decisions on inclusion or exclusion were made by MW and PB. Articles were excluded for several reasons, namely: not a stroke model, NOS inhibitor not administered, outcomes other than infarct volume or CBF, no control group, insufficient other data given, or duplicate publication.

Data Extraction

Infarct volume data (mm^3 or % of normal brain) and CBF data ($ml.min^{-1}.g^{-1}$ or % of baseline readings or baseline control) were extracted for analysis. Infarct volume measurements from the longest period of follow-up were used. CBF measurements after one hour of occlusion or reperfusion were used in permanent and transient stroke respectively. Where possible, regional infarct volume and CBF data were obtained separately for total brain, cortex and sub-cortex. In cases where region was not specified then the measurements were classified as total brain. If an article investigated dose response relationships or optimal timing of administration then data from each individual experimental condition were included separately. In cases where the number of animals in each experiment was given as a range then it was assumed to be the lowest figure. Where numerical values were not available, data were estimated directly from enlarged graphs using a ruler. All data extraction was done by two independent authors (MW, CG); discrepancies were resolved by PB. Finally, the methodological quality of the included articles was assessed on an 8 point scale (Horn et al. 2001) based on published recommendations for investigating new agents in experimental stroke (Stroke Therapy Academic Industry Roundtable (STAIR) 1999); one point was given for written evidence of each of the following factors; (i) randomisation; (ii) monitoring of physiological parameters; (iii) assessment of dose response relationship; (iv) assessment of optimal time window; (v) blinded outcome measurement; (vi) assessment of outcome at day 1-3; (vii) assessment of outcome at day 7-30 and; (viii) combined measurement of infarct volume and functional outcome.

Analysis

Study data were grouped by protocol prior to analysis: (i) experimental model - permanent or transient; (ii) outcome location - total brain, cortex, sub-cortex; (iii) outcome measure - infarct volume (mm^3, %), and CBF ($ml.min^{-1}.g^{-1}$, %). Data from each of these groups were analysed as forest plots using the Cochrane Collaboration Review Manager (RevMan version 4.1) software. Publication bias was assessed using Egger's asymmetry test (Egger et al. 1997) (Stata function 'metabias'). Results are given as standardised mean difference (SMD, reported in units of standard deviation), which allows data measured on different scales to be merged, and 95% confidence intervals (CI). A random effects model was used since statistical heterogeneity, assessed with a χ^2 test, was expected in view of the wide range of protocols. Sensitivity analyses were performed to look at likely sources of heterogeneity, including NOS inhibitor type (grouped as non-selective inhibitors, iNOS inhibitors, nNOS inhibitors), animal species and timing of administration. For the latter, articles were divided into those that administered NOS inhibitors before (pre-treated), 0 to 1 hour after (early treatment) or >1 hour after (late treatment) onset. Meta-regression (STATA, version 7.0) was used to analyse the relationship between timing of administration and the effect on

total infarct volume (SMD) in order to try and determine the size of the therapeutic window. Studies were weighted by sample size and only those that administered NOS inhibitors after onset of ischaemia were included. Significance was set at P<0.05.

RESULTS

Design of studies

Altogether 455 articles were found in the literature search (figure 1). Most of these did not qualify for the review, leaving 72 studies (s). Table 1 summarises the characteristics of the included articles. The most commonly used agents were non-selective inhibitors such as L-NAME (s=37) and L-NNA (s=15). In addition, several compounds were used to target nNOS, including: 7-NI (s=9), AR-R 17477 (s=4), BN 80933, PPBP and TRIM. In contrast, there were only two types of iNOS inhibitor represented: aminoguanidine (s=12) and 1400W. NOS inhibitors were administered to 23 permanent / focal models and to one permanent / global model. More articles assessed the effect of NOS inhibition in transient stroke (29 focal, 13 global and 2 using both). In addition, 2 studies were included which compared a combination of permanent and transient models (Buchan et al. 1994; Dawson et al. 1994). Rats were the animal models used in the majority of studies (24 Sprague Dawley, 21 Wistar, 7 spontaneously hypertensive, 1 Long Evans, 1 Lewis, 1 Fischer). Other studies used diverse species, including; rabbits (Anderson and Meyer 1996; Anderson and Meyer 2000), cats (Clavier et al. 1994; Nishikawa et al. 1993; Nishikawa et al. 1994), mice (Carreau et al. 1994; Ding-Zhou et al. 2002; Goyagi et al. 2001; Gursoy-Ozdemir et al. 2000; Kamii et al. 1996; Nowicki et al. 1991; Sugimoto and Iadecola 2002; Zhu et al. 2002), gerbils (Chabrier et al. 1999; O'Neill et al. 2000; Spatz et al. 1995), pigs (Greenberg et al. 1995; Hiramatsu et al. 1996; Schleien et al. 1998; Segawa et al. 1998), and lambs (Dorrepaal et al. 1997).

Variable methods of drug administration were utilised, e.g. different routes (oral, intra-venous, intra-ventricular, intra-arterial, intra-peritoneal), different timings (1st dose ranging from 6 weeks before to 48 hours after induction of ischaemia) and different dosage regimens (e.g. total administered dose of L-NNA 0.06 – 40.0 mg/kg, L-NAME 0.1mg/kg – 4.2 g/kg, aminoguanidine 100 – 800 mg/kg, ARL-17477 1.0 – 10.0 mg/kg and 7-NI 0.1 – 100 mg/kg). Study design was more consistent for outcome measures. Infarct volumes were assessed by histological staining techniques and image analysis of sequential coronal brain sections in nearly all of the studies. An exception to this were 3 articles that used serial MRI techniques to monitor lesion progression (Cash et al. 2001; Quast et al. 1995; Wei and Quast 1998). Regional CBF after stroke onset was commonly measured as percentage (of baseline or control values) using laser doppler flowmetry (Batteur-Parmentier et al. 2000; Buchan et al. 1994; Goyagi et al. 2001; Greenberg et al. 1995; Gursoy-Ozdemir et al. 2000; Hashimoto et al. 1999; Humphreys and Koss 1998; Iadecola et al. 1996; Iadecola et al. 1995; Jiang et al. 1999; Prado et al. 1993; Sakashita et al. 1994; Santizo et al. 2000; Sugimura et al. 1998; Zhang and Iadecola 1993; Zhao et al. 1999). In addition, one article indirectly assessed total CBF using an ultrasonic flow transducer (Dorrepaal et al. 1997). Alternatively, several studies analysed CBF as $ml.min^{-1}.g^{-1}$ using ^{14}C-iodoantipyrine (Ashwal et al. 1994; Stagliano et al. 1997; Wei et al. 1994), hydrogen clearance (Matsui et al. 1997; Sadoshima et al. 1997; Segawa et al. 1998; Uetsuka et al. 2002), radiolabelled microsphere (Clavier et al. 1994; Hiramatsu et al. 1996; Nishikawa et al. 1993; Nishikawa et al. 1994; Schleien et al. 1998) or umbelliferone fluorescence (Anderson and Meyer 1996; Anderson and Meyer 2000) techniques.

The median quality rating for the included articles was 3 points (range 1-6/8). Treatment was allocated by randomisation in only 16 articles whilst 26 studies assessed dose response; just 13 studies assessed the optimal timing of administration. Most studies examined outcome measures between days 1-3; only 9 did this blinded to treatment whilst 11 looked at functional outcome as well as infarct volume.

Infarct volume and CBF

Collectively, NOS inhibitors caused a significant reduction in total, cortical and sub-cortical infarct volume of magnitude 0.5 to 1.2 standard deviations (table 2). Paradoxically, detrimental effects on CBF were observed in the cerebral cortex of permanent stroke models. Most CBF data came from

studies administering non-selective inhibitors. There was no evidence of publication bias for articles reporting the effect of NOS inhibition on total lesion volume in permanent (Egger's test p=0.33), or transient (Egger's test p=0.65) models. Since heterogeneity was observed in several of the analyses, infarct volume and CBF were further examined by type of NOS inhibitor (table 3), in different animal models (table 4) and by different timings of administration (table 5).

Type of NOS inhibitor
Non-selective inhibitors
In permanent stroke models non-selective inhibitors did not significantly alter infarct volume but did reduce cortical CBF (table 3). By contrast, after transient ischaemia non-selective inhibitors reduced total infarct volume and did not affect CBF (table 3).

nNOS inhibitors
nNOS inhibitors significantly reduced infarct volume in both permanent and transient stroke models (table 3). At 1 hour of reperfusion there was no overall effect on cortical CBF in transient models. However, reduced cortical CBF was seen in one small (n=8) study involving permanent ischaemia.

iNOS inhibitors
Aminoguanidine and 1400W significantly reduced infarct volume in both permanent and transient stroke models. No studies of selective iNOS inhibitors on CBF were identified.

Timing of treatment
Treatment before stroke onset was effective at reducing infarct volume in transient models (table 4) whilst early administration of NOS inhibitors (within 1 hour of onset) was effective in permanent stroke. Later treatment after 1 hour of onset had a beneficial effect on infarct volume in both types of stroke model. Meta-regression analysis found no evidence of a relationship between total infarct volume (SMD) and timing of administration in permanent (p=0.18) or transient (p=0.20) models (figure 3).

Animal Model
Overall, NOS inhibitors appeared to reduce total brain lesion size in agyrencephalic species (table 5) but not in rabbits or cats. Limited data were available on the effects of NOS inhibitors in higher animals.

DISCUSSION

We have examined systematically the effects of NOS-inhibitors on infarct size in experimental stroke models. Apart from 7 studies (Hamada et al. 1995; Kamii et al. 1996; Kuluz et al. 1993; Nakashima et al. 1999; Xu et al. 2000; Yamamoto et al. 1992; Zhang and Iadecola 1993), most of the individual articles were either positive or neutral for this outcome. However, when considered together there was an overall beneficial effect, such that NOS-inhibitors decreased lesion size by about 0.5 to 1.2 standard deviations. Mechanisms that may explain these findings include; reduced formation of peroxynitrite and reactive oxygen species (Caldwell et al. 1995; Gumuslu et al. 1997; Seif-el-Nasr and Fahim 2001; Solenski and Kwan 2000), inhibition of brain oedema (Peeters-Scholte et al. 2002; Quast et al. 1995), reduced vascular damage (Ding-Zhou et al. 2002; Gursoy-Ozdemir et al. 2000), and inhibition of apoptosis and necrosis (Charriaut-Marlangue et al. 1996; Peeters-Scholte et al. 2002). Additional work confirms that NOS inhibitors can increase hippocampal neuronal survival in experimental stroke (Caldwell et al. 1994; Chabrier et al. 1999; Jones et al. 1998; Kohno et al. 1995; Nanri et al. 1998; O'Neill et al. 1996; O'Neill et al. 1997; O'Neill et al. 2000) and improve functional outcome (Chabrier et al. 1999; Ding-Zhou et al. 2002; Gursoy-Ozdemir et al. 2000; Nagayama et al. 1998; Parmentier et al. 1999). However, not all published experimental studies agree with these findings, possibly because of differences in drug pharmacology, dosage, route of administration, timing of treatment, animal model and type of ischaemia. Some of these factors were examined further in this systematic review.

NOS inhibitor type
Non-selective inhibitors did not alter infarct volume in permanent ischaemia, whereas the selective nNOS and iNOS inhibitors reduced lesion size regardless of experimental model. It is likely that the beneficial effects of non-selective inhibitors were limited because they inhibit eNOS to a similar degree as nNOS or iNOS. Consequently, they may aggravate brain ischaemia by increasing platelet aggregation and white cell activity, raising blood pressure, and by restricting penumbral blood supply. Evidence of reduced CBF after administration of non-selective inhibitors to permanent stroke models is consistent with this hypothesis. Hence, the non-selective inhibitors are not agents of first choice for testing in clinical stroke.

Type of experimental model
Indirect assessment of the pooled data in table 2 suggests that NOS inhibitors were equally effective in transient and permanent ischaemia. However, sub-group analysis revealed that non-selective inhibitors did not work in permanent stroke but did in transient stroke (table 3). This discrepancy could be attributed to the presence of additional beneficial effects after transient ischaemia, such as limitation of reperfusion injury caused by eNOS-derived NO (Gursoy-Ozdemir et al. 2000). Alternatively, it could be due to the absence of detrimental effects of non-selective inhibitors in transient models. Consistent with this second theory is the observation that non-specific inhibitors had no detrimental effects on CBF at 1 hour of reperfusion (table 3).

Timing of treatment
The administration of 1st dose varied considerably from 6 weeks prior to 24 hours after onset of ischaemia. Treatment with NOS-inhibitors was effective prior to onset of transient ischaemia, within 1 hour of permanent ischaemia, and even beyond 1 hour of onset in both transient and permanent ischaemia models. The neutral findings seen with pre-treatment of permanent models and early treatment of transient models probably represents the use of non-selective agents and paucity of data rather than lack of response to NOS inhibitors. More important is the confirmation that these agents reduce infarct volume even when administered beyond 1 hour after stroke onset. If NOS-inhibitors are effective beyond the normal neuroprotective window of 2-4 hours, then it is likely that they work through other mechanisms, perhaps enhancing neurogenesis. Also, beneficial activity several hours after stroke suggests that the NOS inhibitors might be useful in clinical

stroke. Unfortunately, meta-regression analysis of timing of administration did not find any evidence of a therapeutic window. More experimental studies with delayed administration are required to assess when the optimum time window closes.

Animal model
Significant infarct reductions after either transient or permanent ischaemia were seen in all rat strains apart from Fischer rats. Only spontaneously hypertensive rats responded to NOS inhibitors in both transient and permanent models. This discrepancy could arise because normotensive strains (SDR, WR, Fischer) suffer smaller and more variable infarcts than SHR (Ginsberg and Busto 1989). In mice, NOS inhibitors worked in permanent but not transient stroke. This inconsistency is most likely due to lack of data, although these studies are complex to assess because different transgenic mouse strains were used. Unfortunately, lack of data prevents any definitive statements about the role of NOS inhibitors in rabbits and cats. More studies need to be performed in lissencephalic and/or gyrencephalic species before clinical trials are commenced, as per the STAIR recommendations (Stroke Therapy Academic Industry Roundtable (STAIR) 1999).

Limitations
Although this study has demonstrated an association between administration of NOS inhibitors and reduced infarct volume, the findings are limited by several factors. First, there were differences between study protocols in terms of animal species, physiological parameters (e.g. blood pressure), drug administration (dosage, route), surgical methodology, and duration of ischaemia. Unfortunately, it is not possible to judge whether the relationships we observed were independent of these factors. In addition, protocol variations can lead to statistical heterogeneity and make the analysis less reliable. To take account of this we used a random effects model and performed sensitivity analyses to identify sources of heterogeneity. Second, some relevant articles may not have been identified for inclusion in the review. Publication bias can contribute to this, either through of lack of reporting of neutral or negative studies or through suppression of positive studies for commercial reasons, e.g. intellectual property rights. This could mean the benefits of NO on infarct volume and CBF have been either over or underestimated. Statistical assessment using Egger's asymmetry test did not suggest the presence of publication bias but the possibility that some relevant data was omitted cannot be ruled out. Third, there were several instances when numerical data were not readily available and we had to derive these directly from published figures. This can be imprecise, although we enlarged graphs and used two authors to extract data. Fourth, some NOS inhibitors work though additional neuroprotective mechanisms that do not only involve inhibition of NO synthesis. Moreover, some of the 'selective' inhibitors only discriminate moderately between iNOS and nNOS (Alderton et al. 2001). Unfortunately, it is not possible to ascertain whether the relationships we have observed in each sub-group are independent of this. Fifth, the technique of extracting multiple pieces of information from single publications has a potential to introduce bias into the review since the results would have been generated by the same investigators / laboratories. Finally, since the median quality rating of the studies was only 3 out of a total of 8, there are likely to be methodological weaknesses in the included studies. Two key areas of concern are that studies are not reporting that they randomised animals to active and control treatment, and performed outcome assessment blinded to treatment assignment. All studies evaluating agents in experimental stroke models should follow published recommendations on preclinical drug development (Stroke Therapy Academic Industry Roundtable (STAIR) 1999).

Accepting these limitations, this systematic review brings together data from all published studies and suggests that NOS inhibitors, especially if 'selective' to nNOS or iNOS, reduce infarct volume in experimental stroke. Non-selective inhibitors may be less effective, probably because they compromise CBF. Consequently, selective NOS inhibitors are candidate treatments for testing in clinical stroke.

ACKNOWLEDGEMENTS

TABLE 1

Included studies

Drug	Studies	Species	Quality	Total N	Model P/T	Occlusion G/F	1st dose timing (min)	route	Measures infarct vol	CBF
Non specific inhibitors										
L-NAME	(Anderson and Meyer 1996)	R	3	42	T	F	-20	i.v.		ml.min^{-1}.g^{-1}
	(Anderson and Meyer 2000)	R	3	15	P	F	-30	i.v.	%	ml.min^{-1}.g^{-1}
	(Ashwal et al. 1993)	SHR	2	14	T	F	-60	i.v.	mm^3	
	(Ashwal et al. 1994)	SHR	3	?	T	F	+0, +120, +150	i.v.	mm^3, %	ml.min^{-1}.g^{-1}, %
	(Ashwal et al. 1995)	SHR	3	14	T	F	-60	i.p.	% , mm^3	
	(Batteur-Parmentier et al. 2000)	SDR	3	110	T	F	+5	i.p.	mm^3	%
	(Buisson et al. 1992)	SDR	2	?	P	F	+5	i.p.	mm^3	
	(Buisson et al. 1993)	SDR	2	50	P	F	-30	i.p.	mm^3	
	(Charriaut-Marlangue et al. 1996)	SDR	1	42	T	F	+5	i.p.	mm^3, %	
	(Clavier et al. 1994)	C	3	24	T	G	+180	i.v.		ml.min^{-1}.g^{-1}
	(Coert et al. 1999)	WR	3	92	T	F	-30	i.v.	mm^3	
	(Dawson et al. 1992a)	SDR	3	18	P	F	-30	s.c	mm^3	
	(Dawson et al. 1994)	SDR	3	67	P, T	F	-30	i.p.	mm^3	
	(Ding-Zhou et al. 2002)	M	4	?	T	F	+180	i.p.	mm^3	
	(Greenberg et al. 1995)	P	4	20	T	G	-60	i.v.		ml.min^{-1}.g^{-1}
	(Hamada et al. 1995)	WR	4	77	P	F	-20	i.c.v.	mm^3	
	(Hiramatsu et al. 1996)	P	2	40	T	G	-?	i.v.		ml.min^{-1}.g^{-1}
	(Humphreys and Koss 1998)	SDR	3	63	T	G	-30	i.v.		%
	(Iuliano et al. 1995)	WR	4	78	T	F	-30	i.v.	mm^3	
	(Kamii et al. 1996)	M	2	?	T	F	+5	i.p.	mm^3	
	(Kuluz et al. 1993)	WR	4	24	T	F	-15	i.v.	mm^3	
	(Margaill et al. 1997)	SDR	4	?	T	F	+5, 180, 360, 540,720	i.p.	mm^3	
	(Nishikawa et al. 1993)	C	4	20	P	F	-30	i.v.	% , mm^3	ml.min^{-1}.g^{-1}
	(Nishikawa et al. 1994)	C	2	49	T	F	-60, +45	i.v.	%	ml.min^{-1}.g^{-1}
	(Prado et al. 1993)	WR	2	14	T	G	-5	i.v.		%
	(Puisieux et al. 2000)	WR	2	52	P	F	-4320	i.p.	mm^3	
	(Quast et al. 1995)	SDR	2	36	T	F	-1	i.v.	mm^3	
	(Schleien et al. 1998)	P	3	18	T	G	-?	i.v.		ml.min^{-1}.g^{-1}

	Reference	Strain			Time	Method	Effect	Route	Unit 1	Unit 2
	(Segawa et al. 1998)	P	4	12	T	G	+90	i.v.		ml.min^{-1}.g^{-1}
	(Sercombe et al. 2001)	SDR	1	37	P	F	-20160, -60480	p.o.	mm^3	
	(Stagliano et al. 1997)	WR	3	29	P	F	+5	i.v.		ml.min^{-1}.g^{-1}
	(Sugimura et al. 1998)	WR	3	18	T	G	-?	?		%
	(Uetsuka et al. 2002)	WR	3	40	T	G	-120	i.v.		ml.min^{-1}.g^{-1}
	(Wei et al. 1994)	LER	2	28	P	F	+15	i.v.		ml.min^{-1}.g^{-1}
	(Wei and Quast 1998)	SDR	2	22	T	F	-1	i.p.	mm^3	
	(Zhang and Iadecola 1993)	SDR	2	31	P	F	+3	i.a.	mm^3	%
	(Zhao et al. 1999)	WR	2	36	T	G	-30	i.p.		%
L-NNA	(Buchan et al. 1994)	WR, SHR	6	?	T, P	G, F	-30 , +5	i.p.	mm^3	%
	(Carreau et al. 1994)	M	3	?	P	F	+5	i.p.	mm^3, %	
	(Dorrepaal et al. 1997)	L	3	18	T	G	+35	i.v. .		%
	(Gursoy-Ozdemir et al. 2000)	M	4	65	T	F	+105	i.p.	mm^3	
	(Hashimoto et al. 1999)	WR	2	?	T	F	-10	i.p., i.a..	%	%
	(Matsui et al. 1997)	SDR	4	148	T	F	-5, +5	i.p.	mm^3	ml.min^{-1}.g^{-1}
	(Nakashima et al. 1999)	WR, FR	1	?	T	F	+120	i.p., i.v. .	mm^3	
	(Nowicki et al. 1991)	M	1	31	P	F	+5	i.p.	mm^3	
	(Sadoshima et al. 1997)	SHR	2	34	T	G	+60	i.v.		ml.min^{-1}.g^{-1}, %
	(Santizo et al. 2000)	SDR	2	26	P	F	-45	i.v.		%
	(Spatz et al. 1995)	MG	2	?	T	G	-240	i.p.		%
	(Spinnewyn et al. 1999)	SDR	3	88	T	F	+240	i.v.	mm^3	
	(Xu et al. 2000)	SDR	1	24	P	F	-30	i.p.	mm^3	
	(Yamamoto et al. 1992)	WR	2	37	P	F	+5	i.v.	mm^3	
	(Zhang et al. 1996b)	WR	3	73	T	F	+120	i.v.	%	%
L-NMMA	(Sakashita et al. 1994)	WR	1	30	T	G	-5	i.p.		%

nNOS inhibitors

	Reference	Strain			Time	Method	Effect	Route	Unit 1	Unit 2
7NI	(Coert et al. 1999)	WR	3	92	T	F	-60	i.p.	mm^3	
	(Escott et al. 1998)	SDR	6	55	T	F	+5, +90	i.p.	%, mm^3	
	(Goyagi et al. 2001)	WR, M	5	115	T	F	-30	i.p.	%	
	(Gursoy-Ozdemir et al. 2000)	M	4	65	T	F	-30, +90	i.p.	mm^3	
	(Humphreys and Koss 1998)	SDR	3	63	T	G	-30	i.v. .		%
	(Jiang et al. 1999)	WR	3	18	T	G	-20	i.p.		%

	(Kamii et al. 1996)	M	2	?	T	F	+5	i.p.	mm^3	
	(Uetsuka et al. 2002)	WR	3	40	T	G	-60	i.p.		ml.min^{-1}.g^{-1}
	(Yoshida et al. 1994)	SDR	3	55	P	F	+5	i.p.	mm^3	
AR-R 17477	(Harukuni et al. 1999)	WR	5	53	P	F	-30, +60	i.v. .	mm^3	
	(O'Neill et al. 2000)	MG, WR	4	?	T	F, G	0, +30, +120	i.v.	mm^3	
	(Santizo et al. 2000)	SDR	2	26	P	F	-45	i.v.		%
	(Zhang et al. 1996b)	WR	3	48	T	F	+120	i.v.	%	%
BN 80933	(Chabrier et al. 1999)	SDR, MG	6	?	T	F, G	+5, 240, 360, 480, 1440	i.v.	mm^3	
PPBP	(Goyagi et al. 2001)	WR, M	5	115	T	F	-30	i.p. .i.v.	%	
TRIM	(Escott et al. 1998)	SDR	6	55	T	F	+5 or 90	i.p.	%, mm^3	

iNOS inhibitors

1400W	(Parmentier et al. 1999)	SDR	3	?	T	F	+1080	s.c.	mm^3	
Aminoguanidine	(Cash et al. 2001)	SDR	3	?	T	F	+360	i.p.	mm^3	
	(Cockroft et al. 1996)	LR	4	?	P	F	+15, 60, 120, 180	i.p.	%	
	(Han et al. 2002)	SDR	3	?	T	F	+0	i.p.	%	
	(Iadecola et al. 1995)	SHR	2	53	P	F	+1440	i.p.	mm^3	%
	(Iadecola et al. 1996)	SDR	2	79	T	F	+360	i.p.	mm^3	
	(Nagayama et al. 1998)	SHR	4	60	P	F	+1440	i.p.	mm^3, %	
	(Sugimoto and Iadecola 2002)	M	3	58	P	F	+1080	i.p.	mm^3	
	(Tsuji et al. 2000)	WR	3	31	P	G	-60	i.p.	%	
	(Xu et al. 2000)	SDR	1	24	P	F	-30	i.p.	mm^3	
	(Zhang et al. 1996a)	SDR	1	71	T	F	+1440	i.p.	mm^3, %	
	(Zhang and Iadecola 1998)	SHR	3	47	P	F	+0	i.p.	mm^3	
	(Zhu et al. 2002)	M	2	75	T	F	+360	i.p.	%	

Abbreviations: Mice (M); Mongolian Gerbil (MG); Piglets (P); Lambs (L); Cats (C); Spontaneously Hypertensive rat (SHR); Sprague-Dawley rat (SDR); Wistar rat (WR); Long-Evans rat (LER); Lewis Rats (LR); Fischer Rats (FR); Rabbits (R); male (M); female (F); permanent (P); transient (T); global (G); focal (F); intra-venous (i.v.); intra-arterial (i.a.); intra-peritoneal (i.p.); infarct volume (infarct vol.); cerebral blood flow (CBF)

TABLE 2

Effect of NOS inhibitors on lesion volume and cerebral blood flow (SMD, 95% CI) by brain region in permanent and transient ischaemia

Outcome	Permanent			Transient		
	Total	Cortical	Sub-cortical	Total	Cortical	Sub-cortical
Lesion volume	-0.51* (-0.82, -0.20) S=19, n=532	-1.13* (-1.57, -0.70) S=15, n=303	-0.57* (-0.92, -0.23) S=13, n=318	-1.01* (-1.29, -0.73) S=28, n=919	-0.69* (-0.94, -0.43) S=12, n=488	-0.40* (-0.74, -0.06) S=11, n=363
CBF	No data	-0.80* (-1.34, -0.27) S=6, n=87	-0.73 (-1.83, 0.36) S=1, n=14	-0.57 (-1.26, 0.11) S=8, n=120	-0.22 (-0.52, 0.07) S=15, n=320	-0.38 (-1.03, 0.26) S=3, n=66

Abbreviations: Standardised mean difference (SMD); cerebral blood flow (CBF); 95% confidence intervals (95% CI); number of studies (S); number of animals (n); *p<0.05

TABLE 3

Effect of selective and non-selective nitric oxide synthase inhibitors on infarct volume and cerebral blood flow (SMD, 95%CI) in stroke models

Inhibitor	Permanent		Transient	
	Total Volume	Cortical CBF	Total Volume	Cortical CBF
Non-selective	0.11 (-0.43, 0.65) S=13, n=258	-0.68* (-1.17, -0.19) S=6, n=83	-0.90* (-1.34, -0.47) S=18, n=455	-0.33 (-0.68, 0.02) S=14, n=266
iNOS	-0.92* (-1.16, -0.69) S=6, n=256	No data	-1.98* (-2.80, -1.15) S=6, n=91	No data
nNOS	-1.36* (-2.05, -0.67) S=1, n=30	-2.62* (-4.89, -0.35) S=1, n=8	-0.90* (-1.28, -0.54) S=7, n=373	+0.12 (-0.38, 0.62) S=4, n=66

Abbreviations: Inducible nitric oxide synthase (iNOS); neuronal nitric oxide synthase (nNOS); standardised mean difference (SMD); cerebral blood flow (CBF); 95% confidence intervals (95% CI); number of studies (S); number of animals (n); *$p<0.05$

TABLE 4

Effect of timing of administration on total infarct volume (SMD, 95%CI)

Model	Timing		
	Pre-treatment	Early	Late
Permanent	+0.40	-0.83*	-1.20*
	(-0.01, 0.81)	(-1.25, -0.41)	(-1.55, -0.86)
	S=8, n=170	S=8, n=249	S=4, n=141
Transient	-1.55*	-0.16	-0.87*
	(-2.11, -0.99)	(-0.98, 0.67)	(-1.24, -0.50)
	S=9, n=191	S=3, n=140	S=11, n=454

Abbreviations: Standardised mean difference (SMD); 95% confidence intervals (95% CI); number of studies (S); number of animals (n); *p<0.05

TABLE 5

Effect of nitric oxide synthase inhibitors by animal model on total infarct volume (SMD, 95%CI)

Model	Spontaneously hypertensive rat	Lewis rat	Sprague Dawley rat	Wistar rat	Fischer rat	Mouse	Rabbit	Cat
Permanent	-0.99* (-1.36, -0.61) S=3, n=135	-0.89* (-1.28, -0.50) S=1, n=80	-0.18 (-0.74, 0.39) S=7, n=152	+1.05 (-0.05, 2.15) S=3, n=55	No data	-1.64* (-2.22, -1.07) S=2, n=68	+1.31* (0.20, 2.42) S=1, n=15	+0.20 (-0.68, 1.08) S=1, n=20
Transient	-2.10* (-2.81, -1.39) S=1, n=51	No Data	-1.15* (-1.56, -0.74) S=9, n=239	-0.61* (-1.10, -0.12) S=5, n=236	+0.69 (-0.06, 1.43) S=1, n=34	-0.91 (-1.90, 0.08) S=3, n=156		-0.05 (-0.81, 0.71) S=1, n=30

Abbreviations: Standardised mean difference (SMD); 95% confidence intervals (95% CI); number of studies (S);

FIGURE 1

Search process showing reasons for exclusion of studies

FIGURE 2a

Total lesion volume by different NOS inhibitor types for permanent models of ischaemia

Comparison: 01 Permanent, total
Outcome:　　01 Lesion volume

Study	Treatment n	mean(sd)	Control n	mean(sd)	SMD (95%CI Random)	SMD (95%CI Random)
01 Non selective inhibitors						
Anderson (1.0) 2000	5	35.00(3.33)	5	32.00(3.07)		0.85[-0.48,2.17]
Anderson (10.0) 2000	5	37.00(0.85)	5	32.00(3.07)		2.00[0.33,3.68]
Buisson 1992	9	125.00(54.00)	9	194.00(42.00)		-1.36[-2.41,-0.31]
Buisson 1993	8	148.00(62.23)	8	225.00(28.28)		-1.51[-2.66,-0.36]
Carreau 1994 (a)	7	3.80(5.29)	7	13.40(6.35)		-1.54[-2.78,-0.29]
Carreau 1994 (b)	7	5.20(5.56)	7	15.20(4.76)		-1.81[-3.12,-0.50]
Carreau 1994 (c)	7	2.90(3.70)	7	12.10(6.61)		-1.61[-2.87,-0.35]
Dawson 1992	9	117.83(31.50)	9	108.50(38.49)		0.25[-0.68,1.18]
Dawson 1994	6	61.75(8.60)	5	72.28(3.13)		-1.43[-2.83,-0.03]
Hamada 1995 (a)	9	48.90(9.90)	11	29.40(11.30)		1.75[0.68,2.81]
Hamada 1995 (b)	11	37.10(14.80)	11	29.40(11.30)		0.56[-0.29,1.42]
Nishikawa 1993	10	2792.00(1125.77)	10	2467.00(1849.93)		0.20[-0.68,1.08]
Puisieux 2000	6	219.00(29.39)	6	227.00(22.05)		-0.28[-1.42,0.86]
Sercombe (2/52) 2001	9	66.00(33.00)	10	57.00(28.46)		0.28[-0.63,1.19]
Sercombe (6/52) 2001	8	57.00(31.11)	10	57.00(28.46)		0.00[-0.93,0.93]
Xu (3h) 2000	6	236.54(49.64)	6	183.34(27.69)		1.22[-0.06,2.50]
Xu (6h) 2000	6	250.36(28.91)	6	199.03(42.65)		1.30[0.00,2.60]
Yamamoto 1992	6	199.20(17.40)	6	150.80(16.60)		2.63[0.92,4.34]
Zhang 1993	5	334.00(55.90)	7	227.00(92.60)		1.24[-0.06,2.53]
Subtotal(95%CI)	139		145			0.11[-0.43,0.65]

Test for heterogeneity chi-square=76.03 df=18 p<0.00001
Test for overall effect z=0.39 p=0.7

Study	Treatment n	mean(sd)	Control n	mean(sd)	SMD (95%CI Random)	SMD (95%CI Random)
03 iNOS inhibitors						
Cockroft 1996 (160)	12	4.00(4.36)	7	7.58(6.69)		-0.65[-1.61,0.32]
Cockroft 1996 (320)	7	1.26(0.56)	7	7.58(6.69)		-1.25[-2.43,-0.07]
Cockroft 1996 120min	8	0.74(0.65)	28	4.85(4.87)		-0.92[-1.74,-0.11]
Cockroft 1996 15min	12	1.29(0.62)	28	4.85(4.87)		-0.85[-1.55,-0.14]
Cockroft 1996 60min	6	0.60(0.11)	28	4.85(4.87)		-0.93[-1.84,-0.02]
Iadecola 1995	10	145.00(25.30)	9	187.00(15.00)		-1.90[-3.03,-0.77]
Nagayama (100) 1998	7	152.00(20.00)	9	177.00(18.00)		-1.25[-2.36,-0.14]
Nagayama (12h) 1998	9	148.00(35.00)	9	185.00(26.00)		-1.14[-2.16,-0.13]
Nagayama (200) 1998	7	142.00(24.00)	9	177.00(18.00)		-1.59[-2.77,-0.42]
Nagayama (400) 1998	5	134.00(25.00)	9	177.00(18.00)		-1.95[-3.34,-0.57]
Nagayama (50) 1998	8	168.00(22.00)	9	177.00(18.00)		-0.43[-1.39,0.54]
Nagayama (6h) 1998	6	161.00(41.00)	9	185.00(26.00)		-0.69[-1.77,0.38]
Sugimoto 2002 (a)	6	22.76(5.07)	6	32.07(5.07)		-1.70[-3.10,-0.29]
Sugimoto 2002 (b)	7	22.24(5.48)	7	31.55(5.48)		-1.59[-2.85,-0.33]
Xu (3h) 2000	6	179.23(21.02)	6	183.34(27.69)		-0.15[-1.29,0.98]
Xu (6h) 2000	6	184.51(23.30)	6	199.03(42.65)		-0.39[-1.54,0.76]
Zhang (24h) 1998	7	204.00(29.10)	6	209.00(29.39)		-0.16[-1.25,0.93]
Zhang (48h) 1998	8	212.00(31.11)	6	219.00(17.15)		-0.25[-1.31,0.81]
Zhang (72h) 1998	6	190.00(29.39)	5	216.00(33.54)		-0.76[-2.01,0.49]
Zhang (96h) 1998	5	152.00(22.36)	4	190.00(22.00)		-1.52[-3.14,0.09]
Subtotal(95%CI)	148		207			-0.92[-1.16,-0.69]

Test for heterogeneity chi-square=17.47 df=19 p=0.56
Test for overall effect z=7.62 p<0.00001

Study	Treatment n	mean(sd)	Control n	mean(sd)	SMD (95%CI Random)	SMD (95%CI Random)
04 nNOS inhibitors						
Yoshida (25.0) 1994	9	237.00(68.00)	13	320.00(58.00)		-1.28[-2.23,-0.34]
Yoshida (50.0) 1994	8	231.00(61.00)	13	320.00(58.00)		-1.45[-2.45,-0.44]
Subtotal(95%CI)	17		26			-1.36[-2.05,-0.67]

Test for heterogeneity chi-square=0.05 df=1 p=0.82
Test for overall effect z=3.87 p=0.0001

Total(95%CI)	304		378			-0.51[-0.82,-0.20]

Test for heterogeneity chi-square=130.94 df=40 p<0.00001
Test for overall effect z=3.21 p=0.001

-4　-2　0　2　4
Favours treatment　Favours control

FIGURE 2b

Cortical CBF by different NOS inhibitor types for transient models of ischaemia

Comparison: 05 Transient, cortical
Outcome: 04 CBF

Study	Treatment n	mean(sd)	Control n	mean(sd)	SMD (95%CI Random)
01 Non selective inhibitors					
Anderson (0.1) 1996	7	51.20(9.26)	7	52.50(7.67)	-0.14[-1.19,0.91]
Anderson (1.0) 1996	7	38.80(5.82)	7	52.50(7.67)	-1.88[-3.22,-0.55]
Anderson (10.0) 1996	7	46.70(21.70)	7	52.50(7.67)	-0.33[-1.39,0.72]
Batteur-Parm 2000	5	75.70(7.14)	5	74.27(7.14)	0.18[-1.06,1.42]
Buchan (WR) 1994	7	89.00(25.00)	7	95.00(24.00)	-0.23[-1.28,0.82]
Buchan(SHR,10.0)1994	7	80.00(34.00)	7	76.00(27.00)	0.12[-0.93,1.17]
Buchan(SHR,2.0) 1994	7	105.00(46.00)	7	76.00(27.00)	0.72[-0.37,1.81]
Buchan(SHR,40.0)1994	7	60.00(45.00)	7	76.00(27.00)	-0.40[-1.47,0.66]
Clavier 1994	6	70.69(12.66)	6	118.10(50.68)	-1.18[-2.46,0.09]
Gursoy-Ozd 2000	7	93.00(31.00)	10	92.00(20.00)	0.04[-0.93,1.00]
Hashimoto 1999	6	74.70(7.90)	6	67.00(4.90)	1.08[-0.17,2.33]
Humphreys (2.0) 1998	6	92.31(25.64)	8	111.39(28.00)	-0.66[-1.76,0.44]
Humphreys (50.0)1998	6	51.28(20.51)	8	111.39(28.00)	-2.24[-3.68,-0.80]
Humphreys(10.0)1998	6	117.95(20.51)	8	111.39(28.00)	0.24[-0.82,1.31]
Matsui 1997 (post)	6	83.04(16.41)	6	70.98(13.13)	0.75[-0.44,1.94]
Matsui 1997 (pre)	6	80.36(16.41)	6	70.98(13.13)	0.58[-0.58,1.75]
Nishikawa 1994 (pre)	10	104.00(41.11)	10	98.00(22.10)	0.17[-0.70,1.05]
Nishikawa 1994(post)	10	94.00(44.27)	10	98.00(22.10)	-0.11[-0.99,0.77]
Prado 1993	8	22.92(16.67)	6	87.50(33.30)	-2.42[-3.92,-0.92]
Sadoshima 1997	13	48.50(18.03)	10	83.00(28.46)	-1.44[-2.38,-0.50]
Segawa 1998	6	23.10(4.00)	6	22.10(1.90)	0.29[-0.85,1.44]
Sugimura 1998	6	70.71(20.99)	6	90.86(30.45)	-0.71[-1.89,0.47]
Uetsuka 2002	5	74.30(12.52)	5	116.90(34.66)	-1.48[-2.97,0.02]
Subtotal(95%CI)	161		165		-0.33[-0.68,0.02]

Test for heterogeneity chi-square=49.20 df=22 p=0.0008
Test for overall effect z=1.84 p=0.07

Study	Treatment n	mean(sd)	Control n	mean(sd)	SMD (95%CI Random)
02 nNOS inhibitors					
Gursoy-Ozd (pre)2000	4	93.00(38.00)	10	92.00(20.00)	0.04[-1.12,1.20]
Gursoy-Ozd(post)2000	6	75.00(18.00)	10	92.00(20.00)	-0.83[-1.90,0.23]
Humphreys 1998	7	174.36(81.41)	8	111.39(28.64)	1.00[-0.10,2.10]
Jiang (100) 1999	3	269.20(39.31)	4	219.70(41.20)	1.03[-0.67,2.74]
Jiang (12.5) 1999	3	224.10(11.60)	4	219.70(41.20)	0.11[-1.39,1.61]
Jiang (25) 1999	4	229.20(45.80)	4	219.70(41.20)	0.19[-1.20,1.58]
Jiang (50) 1999	4	254.90(75.60)	4	219.70(41.20)	0.50[-0.93,1.93]
Uetsuka 2002	5	72.80(9.39)	4	80.00(10.00)	-0.66[-2.04,0.71]
Subtotal(95%CI)	36		48		0.12[-0.38,0.62]

Test for heterogeneity chi-square=8.19 df=7 p=0.32
Test for overall effect z=0.46 p=0.6

Total(95%CI)	197		213		-0.22[-0.52,0.07]

Test for heterogeneity chi-square=59.63 df=30 p=0.001
Test for overall effect z=1.46 p=0.14

-4   -2   0   2   4
Favours treatment   Favours control

Figure 3. Effect of delay until first dose (minutes) on total infarct volume (SMD) in transient ischaemia. Size of circle proportional to size of study.

References

Alderton WK, Cooper CE, Knowles RG. (2001) Nitric oxide synthases: structure, function and inhibition. *Biochem J* 357:593-615

Anderson RE, Meyer FB. (1996) Nitric oxide synthase inhibition by L-NAME during repetitive focal cerebral ischemia in rabbits. *Am J Physiol* 271:H588-594

Anderson RE, Meyer FB. (2000) Is intracellular brain pH a dependent factor in NOS inhibition during focal cerebral ischemia? *Brain Res* 856:220-226

Ashwal S, Cole DJ, Osborne S, Osborne TN, Pearce WJ. (1995) L-NAME reduces infarct volume in a filament model of transient middle cerebral artery occlusion in the rat pup. *Pediatr Res* 38:652-656

Ashwal S, Cole DJ, Osborne TN, Pearce WJ. (1993) Low dose L-NAME reduces infarct volume in the rat MCAO/reperfusion model. *J Neurosurg Anesthesiol* 5:241-249

Ashwal S, Cole DJ, Osborne TN, Pearce WJ. (1994) Dual effects of L-NAME during transient focal cerebral ischemia in spontaneously hypertensive rats. *Am J Physiol* 267:H276-284

Batteur-Parmentier S, Margaill I, Plotkine M. (2000) Modulation by nitric oxide of cerebral neutrophil accumulation after transient focal ischemia in rats. *J Cereb Blood Flow Metab* 20:812-819

Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci U S A* 87:1620-1624

Buchan AM, Gertler SZ, Huang ZG, Li H, Chaundy KE, Xue D. (1994) Failure to prevent selective CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide synthase. *Neuroscience* 61:1-11

Buisson A, Margaill I, Callebert J, Plotkine M, Boulu RG. (1993) Mechanisms involved in the neuroprotective activity of a nitric oxide synthase inhibitor during focal cerebral ischemia. *J Neurochem* 61:690-696

Buisson A, Plotkine M, Boulu RG. (1992) The neuroprotective effect of a nitric oxide inhibitor in a rat model of focal cerebral ischaemia. *Br J Pharmacol* 106:766-767

Caldwell M, O'Neill M, Earley B, Kelly JP, Leonard BE. (1995) NG-nitro-L-arginine methyl ester protects against lipid peroxidation in the gerbil following cerebral ischaemia. *Eur J Pharmacol* 285:203-206

Caldwell M, O'Neill M, Earley B, Leonard B. (1994) NG-Nitro-L-arginine protects against ischaemia-induced increases in nitric oxide and hippocampal neuro-degeneration in the gerbil. *Eur J Pharmacol* 260:191-200

Carreau A, Duval D, Poignet H, Scatton B, Vige X, Nowicki JP. (1994) Neuroprotective efficacy of N omega-nitro-L-arginine after focal cerebral ischemia in the mouse and inhibition of cortical nitric oxide synthase. *Eur J Pharmacol* 256:241-249

Cash D, Beech JS, Rayne RC, Bath PMW, Meldrum BS, Williams SCR. (2001) Neuroprotective effect of aminoguanidine on transient focal ischaemia in the rat brain. *Brain Research* 905:91-103

Chabrier PE, Auguet M, Spinnewyn B, Auvin S, Cornet S, Demerle-Pallardy C, Guilmard-Favre C, Marin JG, Pignol B, Gillard-Roubert V, Roussillot-Charnet C, Schulz J, Viossat I, Bigg D, Moncada S. (1999) BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. *Proc Natl Acad Sci U S A* 96:10824-10829

Charriaut-Marlangue C, Margaill I, Borrega F, Plotkine M, Ben-Ari Y. (1996) NG-nitro-L-arginine methyl ester reduces necrotic but not apoptotic cell death induced by reversible focal ischemia in rat. *Eur J Pharmacol* 310:137-140

Clavier N, Kirsch JR, Hurn PD, Traystman RJ. (1994) Cerebral blood flow is reduced by N omega-nitro-L-arginine methyl ester during delayed hypoperfusion in cats. *Am J Physiol* 267:H174-181

Cockroft KM, Meistrell M, 3rd, Zimmerman GA, Risucci D, Bloom O, Cerami A, Tracey KJ. (1996) Cerebroprotective effects of aminoguanidine in a rodent model of stroke. *Stroke* 27:1393-1398

Coert BA, Anderson RE, Meyer FB. (1999) A comparative study of the effects of two nitric oxide synthase inhibitors and two nitric oxide donors on temporary focal cerebral ischemia in the Wistar rat. *J Neurosurg* 90:332-338

Dawson DA, Graham DI, McCulloch J, Macrae IM. (1994) Anti-ischaemic efficacy of a nitric oxide synthase inhibitor and a N-methyl-D-aspartate receptor antagonist in models of transient and permanent focal cerebral ischaemia. *Br J Pharmacol* 113:247-253

Dawson DA, Kusumoto K, Graham DI, McCulloch J, Macrae IM. (1992a) Inhibition of nitric oxide synthesis does not reduce infarct volume in a rat model of focal cerebral ischaemia. *Neurosci Lett* 142:151-154

Dawson TM, Dawson VL, Snyder SH. (1992b) A novel neuronal messenger molecule in brain: the free radical, nitric oxide. *Ann.Neurol.* 32:297-311

Dimmeler S, Brune B. (1993) Nitric oxide preferentially stimulates auto-ADP-ribosylation of glyceraldehyde-3-phosphate dehydrogenase compared to alcohol or lactate dehydrogenase. *FEBS Lett* 315:21-24

Ding-Zhou L, Marchand-Verrecchia C, Croci N, Plotkine M, Margaill I. (2002) L-NAME reduces infarction, neurological deficit and blood-brain barrier disruption following cerebral ischemia in mice. *Eur J Pharmacol* 457:137-146

Dorrepaal CA, Shadid M, Steendijk P, Van der Velde ET, Van de Bor M, Baan J, Van Bel F. (1997) Effect of post-hypoxic-ischemic inhibition of nitric oxide synthesis on cerebral blood flow, metabolism and electrocortical brain activity in newborn lambs. *Biol Neonate* 72:216-226

Egger M, Davey Smith G, Schneider M, Minder C. (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315:629-634

Escott KJ, Beech JS, Haga KK, Williams SCR, Meldrum BS, Bath PMW. (1998) Cerebroprotective effect of the nitric oxide synthase inhibitors, 1-(2-trifluoromethylphenyl) imidazole (TRIM) and 7-nitro indazole, after transient focal cerebral ischemia in the rat. *J Cereb Blood Flow Metab* 18:281-287

Garthwaite J. (1991) Glutamate, nitric oxide and cell-cell signalling in the nervous system. *Trends Neurosci* 14:60-67

Garvey EP, Oplinger JA, Tanoury GJ, Sherman PA, Fowler M, Marshall S, Harmon MF, Paith JE, Furfine ES. (1994) Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. *J Biol Chem* 269:26669-26676

Ginsberg MD, Busto R. (1989) Rodent models of cerebral ischemia. *Stroke* 20:1627-1642

Goyagi T, Goto S, Bhardwaj A, Dawson VL, Hurn PD, Kirsch JR. (2001) Neuroprotective effect of sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. *Stroke* 32:1613-1620

Greenberg RS, Helfaer MA, Kirsch JR, Traystman RJ. (1995) Effect of nitric oxide synthase inhibition on postischemic cerebral hyperemia. *Am J Physiol* 269:H341-347

Gumuslu S, Serteser M, Ozben T, Balkan S, Balkan E. (1997) Inhibitory role of N omega-nitro-L-arginine methyl ester (L-NAME), a potent nitric oxide synthase inhibitor, on brain malondialdehyde and conjugated diene levels during focal cerebral ischemia in rats. *Clin Chim Acta* 267:213-223

Gursoy-Ozdemir Y, Bolay H, Saribas O, Dalkara T. (2000) Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. *Stroke* 31:1974-1980; discussion 1981

Hamada J, Greenberg JH, Croul S, Dawson TM, Reivich M. (1995) Effects of central inhibition of nitric oxide synthase on focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 15:779-786

Han HS, Qiao Y, Karabiyikoglu M, Giffard RG, Yenari MA. (2002) Influence of mild hypothermia on inducible nitric oxide synthase expression and reactive nitrogen production in experimental stroke and inflammation. *J Neurosci* 22:3921-3928

Handy RL, Wallace P, Gaffen ZA, Whitehead KJ, Moore PK. (1995) The antinociceptive effect of 1-(2-trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide synthase in vitro, in the mouse. *Br J Pharmacol* 116:2349-2350

Harukuni I, Traystman RJ, Kirsch JR. (1999) Effect of AR-R 17477, a potent neuronal nitric oxide synthase inhibitor, on infarction volume resulting from permanent focal ischemia in rats. *Crit Care Med* 27:2508-2511

Hashimoto H, Ohta S, Utsunomiya H, Kumon Y, Sakaki S, Matsuda S, Sakanaka M. (1999) Changes in guanylate cyclase activity in arteriolar smooth muscle cells and hemodynamics after ischemia-reperfusion in rats. *Acta Neuropathol (Berl)* 98:603-613

Hiramatsu T, Jonas RA, Miura T, duPlessis A, Tanji M, Forbess JM, Holtzman D. (1996) Cerebral metabolic recovery from deep hypothermic circulatory arrest after treatment with arginine and nitro-arginine methyl ester. *J Thorac Cardiovasc Surg* 112:698-707

Horn J, deHaan R, Vermeulen M, Luiten PGM, Limburg M, 2045. (2001) Nimodipine in animal model experiments of focal cerebral ischemia. *Stroke* 32:2433-2438

Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. (1996) Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. *Journal of Cerebral Blood Flow and Metabolism* 16:981-987

Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. (1994) Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. *Science* 265:1883-1885

Humphreys SA, Koss MC. (1998) Role of nitric oxide in post-ischemic cerebral hyperemia in anesthetized rats. *Eur J Pharmacol* 347:223-229

Iadecola C, Pelligrino DA, Moskowitz MA, Lassen NA. (1994) Nitric oxide synthase inhibition and cerebrovascular regulation. *J Cereb Blood Flow Metab* 14:175-192

Iadecola C, Zhang F, Casey R, Clark HB, Ross ME. (1996) Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. *Stroke* 27:1373-1380

Iadecola C, Zhang F, Xu X. (1995) Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. *Am J Physiol* 268:R286-292

Iuliano BA, Anderson RE, Meyer FB. (1995) Effect of intermittent reperfusion and nitric oxide synthase inhibition on infarct volume during reversible focal cerebral ischemia. *J Neurosurg* 83:491-495

Jiang MH, Kaku T, Hada J, Hayashi Y. (1999) 7-Nitroindazole reduces nitric oxide concentration in rat hippocampus after transient forebrain ischemia. *Eur J Pharmacol* 380:117-121

Jones PA, Smith RA, Stone TW. (1998) Nitric oxide synthase inhibitors L-NAME and 7-nitroindazole protect rat hippocampus against kainate-induced excitotoxicity. *Neurosci Lett* 249:75-78

Kamii H, Mikawa S, Murakami K, Kinouchi H, Yoshimoto T, Reola L, Carlson E, Epstein CJ, Chan PH. (1996) Effects of nitric oxide synthase inhibition on brain infarction in SOD-1-transgenic mice following transient focal cerebral ischemia. *J Cereb Blood Flow Metab* 16:1153-1157

Kohno K, Ohta S, Furuta S, Kumon Y, Sakaki S. (1995) Intraventricular administration of nitric oxide synthase inhibitors prevents delayed neuronal death in gerbil hippocampal CA1 neurons. *Neurosci Lett* 199:65-68

Kuluz JW, Prado RJ, Dietrich WD, Schleien CL, Watson BD. (1993) The effect of nitric oxide synthase inhibition on infarct volume after reversible focal cerebral ischemia in conscious rats. *Stroke* 24:2023-2029

Margaill I, Allix M, Boulu RG, Plotkine M. (1997) Dose- and time-dependence of L-NAME neuroprotection in transient focal cerebral ischaemia in rats. *Br J Pharmacol* 120:160-163

Matsui T, Nagafuji T, Mori T, Asano T. (1997) N omega-nitro-L-arginine attenuates early ischemic neuronal damage of prolonged focal cerebral ischemia and recirculation in rats. *Neurol Res* 19:192-203

Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander MJ. (1994) Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. *Science* 263:973-977

Nagayama M, Zhang F, Iadecola C. (1998) Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. *J Cereb Blood Flow Metab* 18:1107-1113

Nakashima M, Niwa M, Iwai T, Uematsu T. (1999) Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. *Free Radic Biol Med* 26:722-729

Nanri K, Montecot C, Springhetti V, Seylaz J, Pinard E. (1998) The selective inhibitor of neuronal nitric oxide synthase, 7-nitroindazole, reduces the delayed neuronal damage due to forebrain ischemia in rats. *Stroke* 29:1248-1253; discussion 1253-1244

Nathan C. (1992) Nitric oxide as a secretory product of mammalian cells. *Faseb J* 6:3051-3064

Nishikawa T, Kirsch JR, Koehler RC, Bredt DS, Snyder SH, Traystman RJ. (1993) Effect of nitric oxide synthase inhibition on cerebral blood flow and injury volume during focal ischemia in cats. *Stroke* 24:1717-1724

Nishikawa T, Kirsch JR, Koehler RC, Miyabe M, Traystman RJ. (1994) Nitric oxide synthase inhibition reduces caudate injury following transient focal ischemia in cats. *Stroke* 25:877-885

Nowicki JP, Duval D, Poignet H, Scatton B. (1991) Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. *Eur J Pharmacol* 204:339-340

O'Neill MJ, Hicks C, Ward M. (1996) Neuroprotective effects of 7-nitroindazole in the gerbil model of global cerebral ischaemia. *Eur J Pharmacol* 310:115-122

O'Neill MJ, Hicks C, Ward M, Panetta JA. (1997) Neuroprotective effects of the antioxidant LY231617 and NO synthase inhibitors in global cerebral ischaemia. *Brain Res* 760:170-178

O'Neill MJ, Murray TK, McCarty DR, Hicks CA, Dell CP, Patrick KE, Ward MA, Osborne DJ, Wiernicki TR, Roman CR, Lodge D, Fleisch JH, Singh J. (2000) ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. *Brain Res* 871:234-244

Parmentier S, Bohme GA, Lerouet D, Damour D, Stutzmann JM, Margaill I, Plotkine M. (1999) Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. *Br J Pharmacol* 127:546-552

Peeters-Scholte C, Koster J, Veldhuis W, van den Tweel E, Zhu C, Kops N, Blomgren K, Bar D, van Buul-Offers S, Hagberg H, Nicolay K, van Bel F, Groenendaal F. (2002) Neuroprotection by selective nitric oxide synthase inhibition at 24 hours after perinatal hypoxia-ischemia. *Stroke* 33:2304-2310

Prado R, Watson BD, Wester P. (1993) Effects of nitric oxide synthase inhibition on cerebral blood flow following bilateral carotid artery occlusion and recirculation in the rat. *J Cereb Blood Flow Metab* 13:720-723

Puisieux F, Deplanque D, Pu Q, Souil E, Bastide M, Bordet R. (2000) Differential role of nitric oxide pathway and heat shock protein in preconditioning and lipopolysaccharide-induced brain ischemic tolerance. *Eur J Pharmacol* 389:71-78

Quast MJ, Wei J, Huang NC. (1995) Nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester decreases ischemic damage in reversible focal cerebral ischemia in hyperglycemic rats. *Brain Res* 677:204-212

Radi R, Beckman JS, Bush KM, Freeman BA. (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. *Arch Biochem Biophys* 288:481-487

Reif DW, McCarthy DJ, Cregan E, Macdonald JE. (2000) Discovery and development of neuronal nitric oxide synthase inhibitors. *Free Radic Biol Med* 28:1470-1477

Sadoshima S, Nagao T, Okada Y, Fujii K, Ibayashi S, Fujishima M. (1997) L-arginine ameliorates recirculation and metabolic derangement in brain ischemia in hypertensive rats. *Brain Res* 744:246-252

Sakashita N, Ando Y, Yonehara T, Tanaka Y, Sato K, Uchino M, Ando M. (1994) Role of superoxide dismutase and nitric oxide on the interaction between brain and systemic circulation during brain ischemia. *Biochim Biophys Acta* 1227:67-73

Santizo R, Baughman VL, Pelligrino DA. (2000) Relative contributions from neuronal and endothelial nitric oxide synthases to regional cerebral blood flow changes during forebrain ischemia in rats. *Neuroreport* 11:1549-1553

Schleien CL, Kuluz JW, Gelman B. (1998) Hemodynamic effects of nitric oxide synthase inhibition before and after cardiac arrest in infant piglets. *Am J Physiol* 274:H1378-1385

Segawa D, Hatori N, Yoshizu H, Uriuda Y, Shimizu M, Tanaka S. (1998) The effect of nitric oxide synthase inhibitor on reperfusion injury of the brain under hypothermic circulatory arrest. *J Thorac Cardiovasc Surg* 115:925-930

Seif-el-Nasr M, Fahim AT. (2001) Antioxidant effect of N omega-nitro-L-arginine methyl ester (L-NAME) on global cerebral ischemia in a rat model. *Arzneimittelforschung* 51:628-632

Sercombe R, Issertial O, Seylaz J, Pinard E. (2001) Effects of chronic L-NAME treatment on rat focal cerebral ischemia and cerebral vasoreactivity. *Life Sci* 69:2203-2216

Solenski NJ, Kwan A. (2000) Attenuation of free radical generation during reversible focal cerebral ischemia with the nitric oxide inhibitor, L-NAME (L-N(G)-nitro-L-arginine methyl ester). *Brain Res* 862:262-265

Sorkin LS. (1993) NMDA evokes an L-NAME sensitive spinal release of glutamate and citrulline. *Neuroreport* 4:479-482

Spatz M, Stanimirovic D, Strasser A, McCarron RM. (1995) Nitro-L-arginine augments the endothelin-1 content of cerebrospinal fluid induced by cerebral ischemia. *Brain Res* 684:99-102

Spinnewyn B, Cornet S, Auguet M, Chabrier PE. (1999) Synergistic protective effects of antioxidant and nitric oxide synthase inhibitor in transient focal ischemia. *J Cereb Blood Flow Metab* 19:139-143

Stagliano NE, Zhao W, Prado R, Dewanjee MK, Ginsberg MD, Dietrich WD. (1997) The effect of nitric oxide synthase inhibition on acute platelet accumulation and hemodynamic depression in a rat model of thromboembolic stroke. *J Cereb Blood Flow Metab* 17:1182-1190

Stroke Therapy Academic Industry Roundtable (STAIR). (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. *Stroke* 30:2752-2758

Sugimoto K, Iadecola C. (2002) Effects of aminoguanidine on cerebral ischemia in mice: comparison between mice with and without inducible nitric oxide synthase gene. *Neurosci Lett* 331:25-28

Sugimura T, Sako K, Tohyama Y, Yonemasu Y. (1998) Consecutive in vivo measurement of nitric oxide in transient forebrain ischemic rat under normothermia and hypothermia. *Brain Res* 808:313-316

Tsuji M, Higuchi Y, Shiraishi K, Kume T, Akaike A, Hattori H. (2000) Protective effect of aminoguanidine on hypoxic-ischemic brain damage and temporal profile of brain nitric oxide in neonatal rat. *Pediatr Res* 47:79-83

Uetsuka S, Fujisawa H, Yasuda H, Shima H, Suzuki M. (2002) Severe cerebral blood flow reduction inhibits nitric oxide synthesis. *J Neurotrauma* 19:1105-1116

Wei HM, Chi OZ, Liu X, Sinha AK, Weiss HR. (1994) Nitric oxide synthase inhibition alters cerebral blood flow and oxygen balance in focal cerebral ischemia in rats. *Stroke* 25:445-449; discussion 449-450

Wei J, Quast MJ. (1998) Effect of nitric oxide synthase inhibitor on a hyperglycemic rat model of reversible focal ischemia: detection of excitatory amino acids release and hydroxyl radical formation. *Brain Res* 791:146-156

Welch G, Loscalzo J. (1994) Nitric oxide and the cardiovascular system. *J Card Surg* 9:361-371

Willmot MR, Bath PMW. (2003) The potential of nitric oxide therapeutics in stroke. *Expert Opinion Investigational Drugs* 12:455-470

Xu SJ, Zhang JX, Li Lf, Du XL. (2000) The effects of nitric oxide synthase inhibitors on the early stage of focal cerebral ischaemic injury in rats. *Chinese Pharm Bull* 16:645-647

Yamamoto S, Golanov EV, Berger SB, Reis DJ. (1992) Inhibition of nitric oxide synthesis increases focal ischemic infarction in rat. *J Cereb Blood Flow Metab* 12:717-726

Yoshida T, Limmroth V, Irikura K, Moskowitz MA. (1994) The NOS inhibitor, 7-nitroindazole, decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. *J Cereb Blood Flow Metab* 14:924-929

Young RJ, Beams RM, Carter K, Clark HA, Coe DM, Chambers CL, Davies PI, Dawson J, Drysdale MJ, Franzman KW, French C, Hodgson ST, Hodson HF, Kleanthous S, Rider P, Sanders D, Sawyer DA, Scott KJ, Shearer BG, Stocker R, Smith S, Tackley MC, Knowles RG. (2000) Inhibition of inducible nitric oxide synthase by acetamidine derivatives of hetero-substituted lysine and homolysine. *Bioorg Med Chem Lett* 10:597-600

Zhang F, Casey RM, Ross ME, Iadecola C. (1996a) Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. *Stroke* 27:317-323

Zhang F, Iadecola C. (1993) Nitroprusside improves blood flow and reduces brain damage after focal ischemia. *Neuroreport* 4:559-562

Zhang F, Iadecola C. (1998) Temporal characteristics of the protective effect of aminoguanidine on cerebral ischemic damage. *Brain Res* 802:104-110

Zhang ZG, Reif D, Macdonald J, Tang WX, Kamp DK, Gentile RJ, Shakespeare WC, Murray RJ, Chopp M. (1996b) ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. *J Cereb Blood Flow Metab* 16:599-604

Zhao H, Asai S, Ishikawa K. (1999) Neither L-NAME nor L-arginine changes extracellular glutamate elevation and anoxic depolarization during global ischemia and reperfusion in rat. *Neuroreport* 10:313-318

Zhao X, Haensel C, Araki E, Ross ME, Iadecola C. (2000) Gene-dosing effect and persistence of reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. *Brain Res* 872:215-218

Zhu DY, Deng Q, Yao HH, Wang DC, Deng Y, Liu GQ. (2002) Inducible nitric oxide synthase expression in the ischemic core and penumbra after transient focal cerebral ischemia in mice. *Life Sci* 71:1985-1996